| CAT # | Igama lemveliso | Inkcazo |
| CPD100230 | JBJ-04-125-02 R-isomer | |
| CPD3232 | NTN21277 | I-NTN21277, eyaziwa ngokuba yi-Gefitinib-based PROTAC 3 yi-VHL-recruiting PROTAC eyenza ukuthotywa kwe-EGFR kunye ne-EGFR mutants kunye ne-DC50 ye-11.7 nM kunye ne-22.3 nM ye-HCC827 iseli (Exon 19 del) kunye ne-H3258R cell (L8255R). |
| CPDB3615 | iNazartinib; EGF816; I-NVS-816 | I-Nazartinib, eyaziwa ngokuba yi-EGF816 kunye ne-NVS-816, ifumaneka ngomlomo, ayinakuguqulwa, isizukulwana sesithathu, i-mutant-selective epidermal growth factor receptor (EGFR) inhibitor, enokuthi isebenze i-antineoplastic. |
| CPDB0934 | EAI-045 | I-EAI045 ia inamandla kunye ne-EGFR inhbitor ekhethiweyo. I-EAI045 ijolise ekukhetheni iinguqu ze-EGFR ezinganyangekiyo ngamachiza kodwa igcina i-wild-type receptor. I-EAI045 inqanda i-L858R / T790M-mutant EGFR kunye ne-low-nanomolar potency kwiimvavanyo ze-biochemical. |
| CPDB0101 | Poziotinib | Imiqulu equlethe i-poziotinib iphantsi kophando kulingo lwezonyango lonyango lwe-EGFR-mutant lung adenocarcinoma. |
| CPDB0137 | Osimertinib Mesylate | I-Osimertinib, eyaziwa ngokuba yi-mereletinib kunye ne-AZD-9291, isizukulwana sesithathu se-EGFR inhibitor, ibonise isithembiso kwizifundo ze-preclinical kwaye inika ithemba kwizigulane ezinomhlaza wemiphunga ophezulu oye waxhathisa kwi-EGFR inhibitors ekhoyo. |
